National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

9999 participants

Study Classification

OBSERVATIONAL

Study Start Date

2000-01-01

Study Completion Date

2070-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology.

The objectives of this study are to investigate the incidence and risk factors of large granular lymphocytic leukemia (LGLL) and to analyze the treatment effectiveness, patient prognosis, and healthcare costs in China.

1. Analyze the demographic and clinical characteristics of patients with LGLL, including sex, age, disease severity, and other relevant factors.
2. Examine disease features of LGLL patients, such as biochemical and hematological indicators, LGL counts, clonality, bone marrow pathology, and cytogenetics
3. Assess treatment patterns and real-world effectiveness in LGLL patients.
4. Evaluate clinical outcomes, including hematologic response, relapse, and mortality
5. Investigate long-term prognosis, including post-discontinuation outcomes and health-related quality of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

National Longitudinal Cohort of Hematological Diseases

NCT04645199

Multiple Myeloma Myeloma, Multiple Myelomas, Multiple +16 more

RECRUITING

Evaluation, Treatment, and Training for Patients With Blood Disorders

NCT00001397

Hematologic Diseases

COMPLETED

Progression of Hematopoietic Diseases in Shanghai, China

NCT00365014

Hematologic Diseases

COMPLETED

Biomarker Study for Prediction of aGVHD

NCT03614143

aGVHD

UNKNOWN

Role of aGVHD Biomarkers on aGVHD Risks

NCT04284904

GVHD,Acute Biomarker

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

T-LGL Leukemia NK-LGL Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NICHE-LGLL

Patients who were diagnosed with LGLL in the investigating hospitals from Jan 1, 2000.

A combined retrospective and prospective observational follow-up

Intervention Type OTHER

The NICHE-LGLL will collect basic information, diagnostic and treatment information, as well as health costs information of patients from medical records. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

A combined retrospective and prospective observational follow-up

The NICHE-LGLL will collect basic information, diagnostic and treatment information, as well as health costs information of patients from medical records. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects diagnosed with LGLL.
* Subjects treated at the Institute of Hematology and Blood Diseases Hospital from Jan 1, 2000.

Exclusion Criteria

* Subject unlikely to be available for long-term follow-up for any reason (e.g., inability to obtain follow-up data or presence of severe comorbidities).
* Subject with alcohol or drug dependence that may reduce their compliance with the study.
* Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.

Eligible Sex

ALL

Accepts Healthy Volunteers

No